Amarantus and Brewer Sports Add Partnership With Cavendish Global to #C4CT Alzheimer's Concussion Awareness Summit at United ...
June 11 2014 - 8:00AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports
International (BSI), today announced the addition of Cavendish
Global as partner at the 3rd #C4CT (Coalition for Concussion
Treatment) Concussion Awareness Summit, on Thursday, July 31, 2014
at the United Nations in New York City, NY. The summit will be
focused on the emerging hypothesis that brain injury may increase
the risk of Alzheimer's disease.
Cavendish Global provides family offices and their foundations
with a discrete, peer-to-peer knowledge expansion and relationship
building environment, combined with the innovative resources
required to help develop and implement their individual pro-social
impact investment, grant making and philanthropy programs within
health and the life sciences.
Mr. Michael Moffat, Cavendish co-founder and President explains,
"Brain disorders affect more than 60 million Americans, that's more
than one in four Americans suffering from mental illness or brain
injury. From autism and Alzheimer's disease to traumatic brain
injury (TBI) and post-traumatic stress (PTS), brain ailments cost
the U.S. close to $1 trillion each year. Leading scientists have
uncovered compelling evidence of the link between Traumatic Brain
Injuries and Alzheimer's and Parkinson's disease." Moffat
emphasizes, "Cancer and heart disease affect fewer people, yet
receive three times more funding support than brain diseases. With
recent advances in understanding the link between TBI and brain
ailments, there has never been a better time for pro-social family
offices and foundations to make a real difference by accelerating
the development of new diagnostics and treatments through increased
grant-giving and philanthropy in this important area. Cavendish is
committed to help make this happen."
To register or for additional information, please visit
www.c4ctsummit.com. For further questions, please contact Lindsay
Lommel at lindsay.lommel@thebrewergroup.com.
For sponsorship information please visit:
http://www.c4ctsummit.com/sponsorship-opportunities.
About Cavendish Global
Cavendish Global consists of over 150 leading family offices and
foundations from around the world with combined assets of over $190
billion who share a passion for pro-social endeavors within health
and the life sciences. Cavendish provides family offices with a
number of innovative resources, which includes Cavendish Impact
Forums. A unique gathering of leading family offices, Cavendish
Impact Forums take place three times each year; in the United
States in May, Europe (London, November 2014) and a third event
held at a Cavendish Host Partner City which moves to a different
global location each year (Dubai, UAE January 2015). The
Cavendish Global Health Impact Forum provides family offices with a
discrete, peer-to-peer knowledge expansion and relationship
building environment, combined with the information and educational
resources required by foundations actively seeking to accelerate
technological innovation and health access through sustainable
philanthropy, grant-making, and impact investing. The Forum is also
an opportunity for family offices to champion and share information
on projects and organizations, which they are passionate about with
other family offices from around the world. Cavendish Global Forums
are organized together with the Global Partnerships Forum and the
New York Academy of Sciences.
For more information: http://cavendishglobal.com.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with
neurodegeneration and protein misfolding-related apoptosis. AMBS
has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready
indication for Parkinson's Levodopa induced dyskinesia and Adult
ADHD. AMBS has an exclusive worldwide license to the Lymphocyte
Proliferation test ("LymPro Test(R)") for Alzheimer's disease and
owns the intellectual property rights to a therapeutic protein
known as Mesencephalic-Astrocyte-derived Neurotrophic Factor
("MANF") and is developing MANF-based products as treatments for
brain disorders. AMBS also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). Amarantus operations are
located at Janssen Labs @QB3 in San Francisco, CA. For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
About Brewer Sports International
Brewer Sports International (BSI) is a multi-faceted sports
advisory firm within The Brewer Group Companies with a focus on the
business of sports, wellness and media for professional athletes,
sports agencies, public and private corporations and various
partners including international organizations, governments and
NGOs. Jack Brewer, five-year National Football League (NFL) veteran
and former three-team captain, launched BSI in Minneapolis and
expanded to New York, Dallas, Miami, Beijing and Malawi. BSI offers
a unique financial services platform to professional athletes and
sports agencies, as well as high-net-worth individuals and
businesses related to professional sports. BSI takes pride in
enabling its clients to capitalize on the endless opportunities
presented through sport. For more information, please visit
www.brewersports.com or follow them on Facebook, Twitter and
LinkedIn.
About #C4CT
The Coalition for Concussion Treatment (#C4CT) was founded in
2012 by former NFL player Jack Brewer, CEO of Brewer Sports
International and Gerald Commissiong, President and CEO at
Amarantus BioScience Holdings, Inc. with the goal of bringing
together those who are directly affected by TBI-induced
neurodegenerative diseases with world class researchers,
scientists, and industry leaders whom are actively working towards
identifying and developing innovative TBI treatment opportunities.
#C4CT serves as a platform to spread awareness about concussions
and the severe effects of Traumatic Brain Injury (TBI). #C4CT
fosters the critical discussions and partnerships needed to enhance
research, treatment efforts, and prevention through a global
campaign uniting people who are passionate about the
cause.
CONTACT: Cavendish Global:
Michael Moffat
Co-founder and President Family Office Relations
607.437.0966
michael.moffat@cavenidshglobal.com
Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Director of Investor Relations
408.737.2734 x 101
ir@amarantus.com
Brewer Sports International:
Kristi Hofacker, Interactive Marketing and Media Manager
651.247.4460
kristi.hofacker@thebrewergroup.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024